Recommendations made by the PBAC – December 2021 intracycle meeting


28 January 2022 - Recommendations made by the PBAC in December 2021 relating to the listing of medicines on the PBS have been published.

The PBAC recommended the following medicines:

  • Elexecaftor with tezacaftor and ivacaftor (Trikafta) - patients aged 12 years and older with cystic fibrosis who have at least one F508del mutation in the CFTR gene (F/any population) (new indication). The resubmission from Vertex Pharmaceuticals was not consistent with the Committee's previous advice. Listing is contingent on a price reduction. Watch this space!
  • Lorlatinib (Lorviqua) - patients with stage IIIB (locally advanced) or stage IV (metastatic) non-squamous or not otherwise specified type non-small-cell lung cancer with evidence of an ALK gene rearrangement in tumour material (new indication). Yet another recommendation made on the basis of a comparison against the lowest cost (least costly) alternative. 
  • Clopidogrel hydrogen sulphate (multiple brands) - restriction change
  • Clopidogrel hydrogen sulphate with aspirin (multiple brands) - restriction change
  • Hydroxychloroquine (multiple brands)- restriction change
  • Ibrutinib (Imbruvica) - restriction change
  • Venetoclax (Venclexta) - restriction change
  • Idelalisib (Zydelig) - restriction change
  • Lumacaftor with ivacaftor (Orkambi) - review of Managed Access Program

Read PBAC recommendations

Michael Wonder

Posted by:

Michael Wonder